We report a case of severe hemorrhagic cystitis complicating high-dose cyclophosphamide (CY), total body irradiation and allogeneic hematopoietic stem cell transplantation (HSCT). Supportive care with i.v. hydration, platelet transfusions, continuous bladder irrigation and aluminum irrigation of the bladder was ineffective and the patient developed multiple complications from hemorrhagic cystitis. His condition became critical with persistent bleeding, pulmonary edema and acute renal failure. These problems resolved following successful simple cystectomy and ileal conduit. The patient did not develop any acute or chronic complications following surgery. He is alive with a good quality of life and in third remission after receiving salvage chemotherapy 14 months after his transplantation. Bone Marrow Transplantation (2000) 26, 899-901.
Hemorrhagic cystitis may occur in up to 70% of patients receiving high-dose CY without any prophylaxis. 1 This incidence has been lowered to 6-50% after using a number of prophylactic measures including hyperhydration, polyuric diuresis, bladder irrigation and 2-mercapto-ethanesodium sulphonate (mesna). [1] [2] [3] Despite these measures, hemorrhagic cystitis occasionally causes a substantial morbidity and even mortality in bone marrow transplant patients. The mortality from severe hemorrhagic cystitis has been reported to be 2-4%. 2 In the literature, cystectomy has not been reported as a treatment of hemorrhagic cystitis following HSCT. We report a case of successful cystectomy for severe hemorrhagic cystitis complicated by acute renal failure, and pulmonary edema that occurred following high-dose CY in a patient undergoing an allogeneic HSCT. 
Case report
A pre-B cell lymphoblastic lymphoma was diagnosed in a previously healthy 46 year-old male in December 1997. Cytogenetic studies were normal. Treatment was initiated immediately after diagnosis and consisted of three cycles of cyclophosphamide, adriamycin, vincristine and prednisone (CHOP) followed by l-asparaginase and intrathecal MTX as well as 1800 cGy, cranial irradiation, and three more cycles of CHOP. Following this treatment, he achieved complete remission in May 1998. He then received maintenance therapy with systemic methotrexate. The patient was subsequently referred to the FHCRC for evaluation as a candidate for an autologous HSCT. During the work-up, bone marrow examination revealed lymphoma cells, constituting 5-7% of the total cells of the marrow, on 15 October 1998. The patient underwent a bone marrow transplantation from his HLA-matched sister, following high-dose CY at 60 mg/kg × 2 days and fractionated total body irradiation (TBI) (1.2 Gy × 11) to a total of 13.2 Gy on 6 November 1998. He received MTX and cyclosporine for prophylaxis of acute graft-versus-host disease (GVHD). He received three-way Foley catheter bladder irrigation starting 1 h before the first dose of CY and continued for 24 h after the last dose, at the rate of 500 cc/h of normal saline continuously for the prophylaxis of hemorrhagic cystitis.
His early post-transplant course was complicated by multiorganism bacteremias; CMV antigenemia which was first treated with ganciclovir, resulting in pancytopenia, and then with foscarnet. Upper GI GVHD was treated with oral beclamethasone followed by i.v. methylprednisolone at 1 mg/kg.
On the day of the transplant (day 0), the patient developed hemorrhagic cystitis with moderate suprapubic tenderness, increased urinary frequency and macroscopic clots in the urine. During the following 3 weeks, he received platelet transfusions to stop bleeding as well as smooth muscle relaxants, i.v. hydration and continuous bladder irrigation. All urine cultures were negative for bacteria and viruses (ie BK virus and adenovirus). A bladder ultrasound showed diffuse bladder wall thickness.
In spite of this aggressive supportive care, the hemorrhagic cystitis accelerated over the next month with urinary frequency increasing to every 30-60 min accompanied by extremely painful bladder spasms requiring intravenous narcotics. On day 26, the patient underwent a cystoscopy that revealed a very small and extremely inflamed bladder with a capacity of 50-60 cc consistent with severe CY-induced hemorrhagic cystitis. At this time, he was requiring 1-4 U of blood transfusions weekly. On day 47, the patient underwent aluminum irrigation over 14 h, although he could not tolerate the full 24 h dose because of painful spasms. He was discharged from the hospital on day 50, with intermittent bleeding and on narcotics for pain control.
The patient was readmitted to the hospital with increased, continuous bladder bleeding and severe pain on day 85. Over the next month, the patient received aggressive supportive care, including continuous, high-rate bladder irrigation, platelet transfusions to keep platelets above 100 000 and complete bed rest. Reevaluation by cystoscopy revealed that the bladder capacity had further decreased to 30 cc accompanied by diffuse mucosal bleeding. All cultures including viral cultures continued to be negative. Despite this aggressive therapy, the patient continued having more bleeding episodes causing clot formation in the bladder and eventual acute renal failure from bilateral uretheral obstruction. In preparation for the cystectomy, he received platelet transfusions and 4 units of fresh frozen plasma and developed acute pulmonary edema. The patient was transferred to the intensive care unit and hemodialysis was started. The next day (day 107), the patient underwent cystectomy followed by ileal conduit. During surgery, the bladder was grossly hemorrhagic with necrosis throughout and contained 500 cc blood clot. There was no difficulty requiring special attention with surgery. Following surgery, renal failure and pulmonary edema resolved. The pathologic examination of the bladder revealed severe ulcerative cystitis with hemorrhage and acutely and chronically inflamed granulation tissue. The patient was discharged to the outpatient department on day 121. He was discharged from the hospital to his primary physician on day 157 in good condition, able to ambulate and resume daily activities. During long-term follow-up after the transplant and surgery, the patient has not encountered any complications with the ileal conduit. He developed chronic GVHD of the GI tract as manifested by intermittent nausea, vomiting and anorexia that was successfully treated with long-term steroids. This condition had no impact on the ileal conduit. The patient was able to return to work full-time 9 months after the transplant without any issues with the conduit. His quality of life was good until he was diagnosed with relapse of lymphoma from a bone marrow biopsy during the first year long-term follow-up evaluation. He was treated with rituxan, achieved complete remission and is under evaluation for donor lymphocyte infusion for his relapsed lymphoma.
Discussion
Hemorrhagic cystitis is both a common and possibly lifethreatening complication of high-dose chemotherapy during bone marrow transplantation. Although busulfan, adenovirus, BK virus, and radiation have been claimed as causative factors for hemorrhagic cystitis, it most often occurs following treatment with high-dose CY. 4, 5 Acrolein, a urinary product of CY metabolism by hepatic microsomal enzyme system, is the agent responsible for endothelial damage. 6 Prophylactic measures commonly used for hemorrhagic cystitis in HSCT setting are continuous bladder irrigation, mesna and i.v. hydration. 1, 2 Hemorrhagic cystitis can still occur after these prophylactic measures and can be severe causing pain, prolonged hospitalization and increased morbidity and mortality. Severe HC presents with gross hematuria, clots and accompanying complications.
Several methods have been used to treat complications of severe hemorrhagic cystitis. These include local treatments such as bladder instillation of aluminum, formalin, phenol, silver nitrate and prostaglandin or surgical methods such as cystoscopy, suprapubic cystotomy, and open cystotomy with simultaneous urinary diversion. 7, 8 Patients who require a surgical procedure such as cystotomy have a higher mortality than patients whose HC resolves with medical management only. 7 There are few reports of cystectomy to treat hemorrhagic cystitis. A woman with breast cancer who received oral CY developed acute hemorrhagic cystitis, required cystectomy to control bleeding during the acute phase and underwent successful reconstruction with neobladder. 9 Cystectomy in bladder cancer patients may be associated with less than 5% mortality rate and limited morbidity such as sexual dysfunction and urinary diversion problems, however, quality of life remains good. 10, 11 There are no previous reports of cystectomy to treat hemorrhagic cystitis following HSCT. At the FHCRC, several patients with severe hemorrhagic cystitis died of renal, infectious or bleeding complications before a decision to conduct such a procedure was made (unpublished data). Although most patients with moderate to severe hemorrhagic cystitis can be treated conservatively, patients who require bladder tamponade, as in our case, have a high mortality and require surgical intervention. Our feeling is that patients who have severe hemorrhagic cystitis and related complications are at high risk for a poor outcome. Therefore, we suggest cystectomy should not be delayed to conserve the bladder in patients with severe hemorrhagic cystitis.
